Company & Sponsor Intelligence

Encoded Therapeutics

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials3

Recruiting2

Completed0

Countries3

Therapeutic footprint

epilepsy

Indexed studies

NCT06283212A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome
epilepsy · United KingdomPHASE1, PHASE2

NCT06112275A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)
epilepsy · AustraliaPHASE1, PHASE2

NCT04537832Natural History Study of Infants and Children With Developmental and Epileptic Encephalopathies
epilepsy · United StatesTERMINATED

Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →